In short
Clinical trials are studying Gns561 in people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. The main goal is to see whether adding Gns561 to standard treatment can improve outcomes, especially progression-free survival. The trial also looks at first-line treatment in adults with this condition.
Key points
- Clinical trials are studying Gns561 in people with unresectable hepatocellular carcinoma, which is liver cancer that cannot be removed with surgery. The main trial is a Phase 2 study and includes 196 participants. It tests Gns561 with standard first-line treatment versus standard treatment alone. The main outcome is progression-free survival, which measures how long patients live without the cancer getting worse. The study is completed and uses a randomized design, meaning people are assigned to treatment groups by chance.
Trial overview
The main study in the data is NCT05448677, called ABE-LIVER, which is a randomized Phase 2 trial in unresectable hepatocellular carcinoma. It studies Gns561 as part of first-line treatment, meaning the first treatment given for this cancer. The study is completed and planned to include 196 participants.
Who the trial is for
This trial is for people with unresectable hepatocellular carcinoma, which is a liver cancer that cannot be removed with surgery. The study focuses on patients who need first-line treatment for this condition.
What treatment is being tested
The trial compares standard treatment with and without Gns561. The standard treatment in the study is atezolizumab-bevacizumab, and Gns561 is given in the treatment arm being tested. The source also lists several brand names linked to bevacizumab and atezolizumab used in the study record, but the key research question is whether adding Gns561 improves results compared with standard care alone.
Trial design and phase
This is an interventional study, which means researchers assign the treatment rather than only observing usual care. It is a Phase 2 trial, a stage that usually looks at whether a treatment may work well enough to justify further study. The trial uses randomization, so participants are assigned to groups by chance.
What the trial measures
The main endpoint is progression-free survival (PFS). PFS means the time from randomization until the cancer gets worse or the person dies from any cause, whichever happens first. The study uses a centralized tumor response assessment and RECIST version 1.1, which is a standard way to measure changes in tumors on scans.
What this means for patients
For patients, this trial asks a simple but important question: can adding Gns561 to standard first-line treatment help people with unresectable hepatocellular carcinoma stay free from cancer growth for longer? Because the study is completed, the trial record gives a clear picture of the research plan, including the target population, phase, and main outcome being measured.